State records show 89 hospice companies at one Los Angeles office plaza. We went to look for ourselves.

89 licensed hospice companies were registered at a single Los Angeles office building (Merabi Plaza); CBS found 72 of those 89 exhibited at least three regulatory warning signs. A 2022 California State Auditor report noted a 1,500% increase in hospice companies in Los Angeles County since 2010, and federal inspections from 2021–2025 flagged nearly 400 violations across 75 firms. Regulators (California AG, CMS) say enforcement and payment-stoppage efforts have accelerated, implying heightened reimbursement and legal risk for hospice operators that could pressure the sector.

Analysis

Regulatory escalation in hospice is a structural supply-side shock: aggressive audits and pre-payment scrutiny will disproportionately shrink revenues of small, paper-heavy providers and raise working capital stress. Expect 12–24 months for CMS/state enforcement to translate into measurable claim recoveries and provider closures; conservatively model 10–30% revenue attrition among subscale hospices exposed to clustering and shared-staff models.

Consolidation tailwinds favor operators with enterprise-grade compliance, strong EMR integration, and diversified post-acute footprints — they can absorb higher audit costs and win displaced referrals. That creates a durable margin gap: large, compliant chains should see a 200–500bp relative margin improvement versus fragmented peers as lower-quality entrants exit or are de-risked by payers.

Second-order effects hit commercial stakeholders: vendors selling revenue-cycle, identity-verification, and fraud-detection software should see a 20–40% uptick in procurement cycles; state AG enforcement and CMS payment holds increase Medicare cash-recovery volatility, tightening short-term liquidity across the provider ecosystem. On real estate, localized tenant “papering” disguises vacancy risk in small medical-office portfolios — expect higher capex/leasing costs and selective repricing in submarkets with known clustering within 6–12 months.

Key Decisions for Investors

• Pair trade (6–18 months): short Amedisys (AMED) 3–6 month out-of-the-money puts sized for 3–5% portfolio exposure / long UnitedHealth Group (UNH) 6–12 month calls of equal notional. Rationale: regulatory pain will compress margins of standalone hospice providers while payers benefit from reduced leakage and stronger utilization management. Risk/Reward: asymmetric — ~25% downside scenario on AMED vs ~10–15% upside on UNH; hedge reduces idiosyncratic market beta.
• Long compliance/analytics exposure (6–12 months): buy NICE Ltd (NICE) or similar revenue-cycle/fraud-detection vendors — initiate 2–3% portfolio position in stock or buy-call spread. Rationale: accelerated procurement from hospice/payer audits; expect revenue growth acceleration +15–30% in vendor bookings. Risk: procurement cycles can be slow; cap gains likely by enforcement headlines.
• Short select small-cap medical-office REIT exposure in concentrated LA submarkets (3–12 months): trim/short Physicians Realty Trust (DOC) or Healthcare Trust of America (HTA) weight in favor of diversified life-science REITs. Rationale: tenant churn and hidden vacancy from paper hospices will pressure rents and raise leasing costs in specific submarkets. Risk/Reward: local downside 10–20% vs macro office repricing could offset—use tight stops and geographic screens.
• Event hedge (3–9 months): buy out-of-the-money puts on CHROMED or AMED (if available) around major CMS/state enforcement announcements; alternatively, buy 3–6 month VIX/market-put protection sized to 1–2% portfolio. Rationale: enforcement headlines create episodic vol spikes and reprice small-cap healthcare segments. Risk: cost of carry if no headline; offsets concentrated short exposures.